Oppilan Pharma is a clinical-stage biopharmaceutical company focused on developing novel small molecule therapeutics for the treatment of autoimmune diseases. Our lead drug candidate, OPL-002, is a potent and selective modulator of sphingosine 1 phosphate receptor subtype 1 (S1P1) under development for the treatment of inflammatory bowel disease. We initiated a Phase 1 clinical study with OPL-002 in December 2018.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.